ReviewFrontiers in oncology2026
The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biochemical recurrence after radiotherapy is common and clinically challenging in prostate cancer (PCa), as accurate restaging is required to identify patients eligible for local salvage therapy and distinguish them from those requiring systemic or metastasis-directed treatment. This review evaluates the diagnostic value of multiparametric MRI (mpMRI) and prostate-specific membrane antigen-targeted PET/CT (PSMA-targeted PET/CT) for restaging radiorecurrent prostate cancer. Methods: A narrative review was conducted using PubMed and Scopus. Original English-language studies published within the last 10 years were included if they reported the diagnostic performance of mpMRI, PSMA-targeted PET/CT, or combined imaging in patients with suspected radiorecurrent prostate cancer, using histopathology as the reference standard. Evidence was synthesized with particular attention to intraprostatic recurrence, extraprostatic disease, and imaging performance after brachytherapy. Results: Ten studies (4 prospective and 6 retrospective) met the inclusion criteria. mpMRI demonstrated heterogeneous sensitivity for intraprostatic recurrence with moderate-to-high specificity (64-87%), and frequently underestimated multifocal disease, particularly in the post-brachytherapy setting. PSMA-targeted PET/CT showed high sensitivity for intraprostatic recurrence (up to ~89%) and superior detection of nodal and distant metastases, although very small or low-PSMA-expressing intraprostatic lesions may remain undetected. The combination of mpMRI and PSMA-targeted PET/CT provided the highest diagnostic confidence: concordant findings achieved a positive predictive value of 97.6%, supporting improved patient selection for salvage treatment strategies. Conclusions: mpMRI and PSMA-targeted PET/CT provide complementary diagnostic information rather than being interchangeable modalities. A multimodal imaging approach improves restaging accuracy in radiorecurrent prostate cancer and may better guide biopsy targeting and selection of candidates for salvage therapy. Nevertheless, histological confirmation remains mandatory before local salvage treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.